

[>> Download this market research report on Reportlinker.com](#)

Point of Care Diagnostic Testing World Markets

Published on November 2009

Report Summary

This report describes latest developments in the point of care diagnostic testing (POCT) market segment. It examines clinical instruments, devices and reagents and supplies as utilized in near-patient environments like hospital emergency rooms, critical care units, clinics and doctor's offices. The study defines the dollar volume of point of care sales and makes five year projections--both in the U.S. and worldwide--including Europe, Asia and Latin America. It also examines in detail the point of care sector for 25 individual country markets. The current market condition of all clinical segments involving point of care testing is examined. A detailed summary of all important instruments in each clinical market is provided with emphasis on newly introduced products. Also, parallel areas where rapid detection is important using hand held devices such as rapid detection of food pathogens and infectious pathogens (MRSA, herpes simplex, avian flu, West Nile virus and typhoid) are discussed. Growth moderators and developing trends in point of care applications, as well as technology platform innovations and connectivity questions are discussed in detail. The report surveys almost all of the companies known to be marketing, manufacturing or developing instruments and reagents for the point of care market in the U.S and worldwide, including China and India. Each company is discussed in depth, with a section on its history, product line, business and marketing analysis, and a subjective commentary of the company's market position.

Table of Content

1. Overview

- 1.1 About this Report
- 1.2 Scope of the Report
- 1.3 Objectives
- 1.4 Methodology
- 1.5 Executive Summary

2. Overview of Diagnostic Testing Point of Care

- 2.1 Point of Care Testing Sites
- 2.2 Point of Care Market Structure
- 2.3 New Directions in Clinical IVD Testing

3. POCT and Rapid Testing Market Analysis: Size, Background Analysis, Growth, Share and Competitors

- 3.1 Global POCT Market
- 3.2 U.S. POCT Market
- 3.3 European POCT Market
 - 3.3.1 German POCT Diagnostic Market
 - 3.3.2 U.K. POCT Diagnostic Market
 - 3.3.2.1 U.K. POCT Market Statistics
 - 3.3.2.2 U.K. Competitive Analysis

- 3.3.2.3 U.K. Market Access
- 3.3.3 French POCT Diagnostic Market
- 3.3.4 Italian POCT Diagnostic Market
- 3.3.5 Spanish POCT Diagnostic Market
- 3.3.6 Scandinavian POCT Diagnostic Market
- 3.3.7 Swedish POCT Diagnostic Market
- 3.3.8 Finnish POCT Diagnostic Market
- 3.3.9 Norwegian POCT Diagnostic Market
- 3.3.10 Swiss POCT Diagnostic Market
- 3.3.11 Dutch POCT Diagnostic Market
- 3.3.12 Belgian POCT Diagnostic Market
- 3.3.13 Portuguese POCT Diagnostic Market
- 3.3.14 Austrian POCT Diagnostic Market
- 3.3.15 Greek POCT Diagnostic Market
- 3.3.16 Polish POCT Diagnostic Market
- 3.3.17 Czech Republic POCT Diagnostic Market
- 3.3.18 Turkish POCT Diagnostic Market
- 3.4 Asian POCT Markets
 - 3.4.1 Japanese POCT Diagnostic Market
 - 3.4.2 Indian POCT Diagnostic Market
 - 3.4.3 Chinese POCT Diagnostic Market
- 3.5 Rest of the World POCT Market
 - 3.5.1 Canadian POCT Diagnostic Market
 - 3.5.2 Brazilian POCT Diagnostic Market
 - 3.5.3 Australian POCT Diagnostic Market
- 3.6 Overview of Asian Healthcare Market
 - 3.6.1 Singapore
 - 3.6.2 Malaysia
 - 3.6.3 Thailand
 - 3.6.4 Indonesia
 - 3.6.5 Philippines
 - 3.6.6 South Korea
 - 3.6.7 Taiwan

4. POCT Individual Markets

- 4.1 Glucose Testing
- 4.2 POCT Individual Market Sectors, Size, Growth Rates and Competitors
 - 4.2.1 World Market
 - 4.2.2 U.S. Market
 - 4.2.3 European Market
 - 4.2.4 Alternate Glucose Monitoring Products
 - 4.2.5 HbA1c POCT
- 4.3 Blood Gas and Electrolytes
 - 4.3.1 Whole Blood Lactate
- 4.4 Rapid Coagulation Tests
 - 4.4.1 World POCT Coagulation Market
 - 4.4.2 U.S. Coagulation Market
 - 4.4.3 European Coagulation Market
 - 4.4.4 Trends in POCT Coagulation Testing

- 4.5 Rapid Cardiac Markers
 - 4.5.1 U.S. Market
 - 4.5.2 European Market
- 4.6 Drugs of Abuse Screening Testing
 - 4.6.1 Acetaminophen
 - 4.6.2 Tricyclic Antidepressants (TCAs)
 - 4.6.3 Other Toxic Drugs
 - 4.6.4 Drug Testing Selectivity
 - 4.6.5 Methaqualone and Phencyclidine (PCP)
 - 4.6.6 Tetrahydrocannabinol
 - 4.6.7 Drug Panels by Toxidromes
 - 4.6.8 Alcohol Testing
- 4.7 Urine Strips
- 4.8 Pregnancy Tests
- 4.9 Fecal Occult Blood
- 4.10 Hemoglobin Testing
- 4.11 Miscellaneous Rapid Tests
 - 4.11.1 Estriol
 - 4.11.2 Fetal Fibronectin (fFN)
 - 4.11.3 H. pylori
 - 4.11.4 Vaginal pH and Vaginitis
 - 4.11.5 Bladder Cancer
 - 4.11.6 Fetal Status
 - 4.11.7 Heparin-induced Thrombocytopenia
- 4.12 Human Immunodeficiency Virus (HIV)
- 4.13 Cholesterol
- 4.14 Infectious Disease
 - 4.14.1 Clostridium difficile
 - 4.14.2 Giardia
 - 4.14.3 Salmonella and Campylobacter
 - 4.14.4 Malaria Testing
 - 4.14.5 Influenza Testing
 - 4.14.6 Strep Testing
 - 4.14.7 Chlamydia
 - 4.14.8 Mononucleosis
 - 4.14.9 Rubella
 - 4.14.10 Methicillin-resistant Staphylococcus Aureus (MRSA)
 - 4.14.11 Hepatitis
 - 4.14.12 Gonorrhea
 - 4.14.13 Tuberculosis (TB)
 - 4.14.14 Herpes Simplex Virus Type-2
- 4.15 Infant Jaundice
- 4.16 Anthrax
- 4.17 Rupture of Fetal Membranes (ROM)
- 4.18 Food Pathogens
- 4.19 Typhoid

5. POCT: Reagents and Equipment

- 5.1 Blood Glucose Monitoring

- 5.1.1 LifeScan
- 5.1.2 Roche Accu-Chek
- 5.1.3 Siemens Healthcare Diagnostics
- 5.1.4 Cholestech (Acquired by Inverness Medical Innovations)
- 5.1.5 Abbott Diabetes Care
- 5.1.6 International Technidyne Corporation
- 5.1.7 HemoCue
- 5.1.8 Stanbio/GDS Technology
- 5.1.9 Disetronic Medical Systems
- 5.1.10 Medtronic MiniMed
- 5.1.11 Abaxis, Inc.
- 5.1.12 Arkray
- 5.1.13 Nova Bio
- 5.1.14 Accurex (India)
- 5.1.15 Axis-Shield
- 5.1.16 Home Diagnostics, Inc.
- 5.1.17 Medisys/Hypoguard
- 5.1.18 Diametrics Medical
- 5.1.19 Metrika
- 5.1.20 Nova Biomedical
- 5.1.21 DexCom, Inc.
- 5.1.22 Bayer
- 5.1.23 Biosite
- 5.2 Blood Gas and Electrolytes
 - 5.2.1 Roche Corporation
 - 5.2.2 TechnoMedica
 - 5.2.3 Siemens Healthcare Diagnostics
 - 5.2.4 Instrumentation Laboratory
 - 5.2.5 Nova Biomedical
 - 5.2.6 Radiometer
 - 5.2.7 Abbott Laboratories
 - 5.2.8 Span Diagnostics
 - 5.2.9 Avox Systems
 - 5.2.10 ITC
 - 5.2.11 OPTImedical
- 5.3 Rapid Coagulation Tests
 - 5.3.1 POC Coagulation Instrument Description
 - 5.3.1.1 Roche Diagnostics Corp.
 - 5.3.1.2 Abbott Laboratories
 - 5.3.1.3 International Technidyne Corporation
 - 5.3.1.4 Medtronic
 - 5.3.1.5 HemoSense (Inverness)
 - 5.3.1.6 Helena Laboratories Point of Care
 - 5.3.1.7 Sienco, Inc.
 - 5.3.1.8 Accumetrics
 - 5.3.2 Connectivity Issues
 - 5.3.3 Cost Benefits
 - 5.3.4 Quality Control Issues
 - 5.3.5 Certification for Point of Care Coagulation Devices
- 5.4 Rapid Cardiac Markers

- 5.4.1 Nanogen
- 5.4.2 Biosite Diagnostics (Inverness)
- 5.4.3 Roche Diagnostics
- 5.4.4 Ani Biotech
- 5.4.5 Response Biomedical Corporation
- 5.4.6 Siemens Healthcare Diagnostics (f/k/a Bayer Healthcare Diagnostics, Diagnostic Products Corporation, and Dade Behring)
- 5.4.7 Lab21 Ltd.
- 5.4.8 Abbott Laboratories
- 5.4.9 LifeSign (Princeton BioMediTech Corp.)
- 5.4.10 Mitsubishi Kagaku Iatron
- 5.5 Rapid Drugs of Abuse
 - 5.5.1 Biosite Diagnostics (now a brand of Inverness Medical Innovations)
 - 5.5.2 Abbott Diagnostics
 - 5.5.3 Roche Diagnostics
 - 5.5.4 BioScan Screening Systems, Inc.
 - 5.5.5 American Bio Medica Corp.
 - 5.5.6 Phamatech, Inc.
 - 5.5.7 Worldwide Medical
 - 5.5.8 OraSure
 - 5.5.9 LifePoint
 - 5.5.10 Avitar, Inc.
 - 5.5.11 Cozart Biosciences
 - 5.5.12 Pathtech
 - 5.5.13 Alfa Scientific Designs, Inc.
 - 5.5.14 TCPI, Inc.
 - 5.5.15 Roche
 - 5.5.16 Siemens Corporation
 - 5.5.17 Diagnostic Chemical Ltd.
 - 5.5.18 Quidel
 - 5.5.19 HemoCue (Quest)
 - 5.5.20 Biophor Diagnostics
- 5.6 Rapid Pregnancy and Fertility Tests
- 5.7 Fecal Occult Blood
 - 5.7.1 Helena Laboratories
 - 5.7.2 Biomerica
 - 5.7.3 Beckman Coulter
 - 5.7.4 Worldwide Medical
 - 5.7.5 Aerscher Diagnostics
 - 5.7.6 Enterix
 - 5.7.7 Medix Biochemica
 - 5.7.8 Orion Diagnostica
- 5.8 Hemoglobin Testing
 - 5.8.1 Wampole Laboratories
 - 5.8.2 HemoCue, Inc.
 - 5.8.3 Stanbio/GDS Technology
- 5.9 Miscellaneous Rapid Tests
 - 5.9.1 Triage C. difficile Panel
 - 5.9.2 Ketoacids
 - 5.9.3 Acetaminophen
 - 5.9.4 Estriol

- 5.9.5 H. pylori
- 5.9.6 Vaginal Fluid pH and Vaginitis
- 5.9.7 Prostate-specific Antigen (PSA)
- 5.9.8 Bladder Cancer
- 5.9.9 Other Rapid Cancer Tests
- 5.9.10 Fetal Status (PROM)
- 5.9.11 Osteoporosis
- 5.9.12 Hemodynamic Monitoring
- 5.9.13 Heparin-induced Thrombocytopenia
- 5.10 HIV
 - 5.10.1 Whole Blood, Serum or Plasma-based HIV Tests
 - 5.10.1.1 Bio-Rad Laboratories
 - 5.10.1.2 Orgenics (wholly-owned by Inverness Medical Innovations)
 - 5.10.1.3 StatSure Diagnostic Systems
 - 5.10.1.4 Trinity Biotech
 - 5.10.1.5 Savyon Diagnostics
 - 5.10.1.6 MedPharm
 - 5.10.1.7 American Bio Medica Corp.
 - 5.10.1.8 Chembio Diagnostics
 - 5.10.1.9 OraSure Technologies
 - 5.10.1.10 Inverness
 - 5.10.2 Saliva-based HIV Tests
 - 5.10.2.1 OraSure Collection Device
 - 5.10.2.2 SureStat
 - 5.10.3 Urine-based HIV Tests
 - 5.10.3.1 MedMira Laboratories, Inc.
 - 5.10.3.2 Medical Services International, Inc.
 - 5.10.3.3 Maxim Biomedical
 - 5.10.3.4 Wampole Laboratories
- 5.11 Cholesterol
 - 5.11.1 Cholestech (now a brand of Inverness Medical Innovations)
 - 5.11.2 Actimed Laboratories
 - 5.11.3 StatSite Meter
 - 5.11.4 Polymer Technology Systems
 - 5.11.5 PreMD, Inc. (f/k/a International Medical Innovations, Inc. [IMI])
 - 5.11.6 Abaxis, Inc.
- 5.12 Infectious Disease
 - 5.12.1 C. difficile
 - 5.12.2 Giardia
 - 5.12.3 Dengue Fever
 - 5.12.4 Malaria Testing
 - 5.12.5 Rapid Influenza Testing
 - 5.12.6 Streptococcus Testing
 - 5.12.7 Chlamydia
 - 5.12.8 Mononucleosis
 - 5.12.9 Rubella
 - 5.12.10 Staphylococcus Aureus and MRSA
 - 5.12.11 Hepatitis
 - 5.12.12 E. Coli O157
 - 5.12.13 Gonorrhea Testing

- 5.12.14 Smallpox
- 5.12.15 SARS
- 5.12.16 Rabies
- 5.12.17 Tuberculosis
- 5.12.18 Avian Flu
- 5.12.19 West Nile Virus
- 5.12.20 Herpes Simplex Virus Type-2
- 5.13 Infant Jaundice
- 5.14 Anthrax
- 5.15 Homeland Defense (Plague and Tularemia)
- 5.16 BSE (Mad Cow Disease)
- 5.17 Tuberculosis
- 5.18 Typhoid
- 5.19 Avian Flu
- 5.20 Food Pathogens (Salmonella, Listeria, Campylobacter)
- 5.21 Ruptured Fetal Membranes (ROM)

6. POCT: Growth Regulators

- 6.1 Moderators of Growth
- 6.2 Personnel Acceptance
- 6.3 Key People for POCT
- 6.4 Information Management Issues
 - 6.4.1 Elements of Information Management for POCT: Information Processing Capabilities
 - 6.4.2 Data Mining
 - 6.4.3 Middleware
 - 6.4.4 Web Portals
 - 6.4.5 POCT-1A Standard
- 6.5 Key Elements for POCT
- 6.6 POCT and Reimbursement
- 6.7 Effectiveness of Clinical Outcomes
- 6.8 Rapid Near-Patient Testing in Hospitals
- 6.9 Satellite Facilities
- 6.10 Regionalization of Laboratory Care
- 6.11 Requirements for POCT
- 6.12 Locations of Point of Care for Patient Care
- 6.13 Benefits of POCT
- 6.14 Cost Elements of POCT
- 6.15 Necessary Functions in POCT
- 6.16 TAT for POCT
- 6.17 Clinical Laboratory Improvement Amendments (CLIA)
- 6.18 Sexually-Transmitted Diseases in Underdeveloped Countries

7. Business Trends in the Point of Care Sector

- 7.1 Sector Consolidation
- 7.2 Diagnostic Testing Growth Trends
- 7.3 Acquisition, License Agreements, Internal Development and Partnerships
- 7.4 Product Testing Depth in POCT
- 7.5 Government Regulation

- 7.5.1 U.S. Regulation
 - 7.5.1.1 Importing Medical Devices into the U.S.
 - 7.5.1.2 Exporting Medical Devices from the U.S.
- 7.5.2 U.K. Regulation
- 7.5.3 E.U. Regulation
 - 7.5.3.1 French Regulation
- 7.5.4 Japanese Regulation
- 7.5.5 Korean Regulation
- 7.6 Increased Market Penetration
- 7.7 Costs of Doing Business in Europe
- 7.8 Drivers of European Diagnostics Testing
- 7.9 European Reimbursement Practices
- 7.10 Cost Containment in Europe

8. Technology Platform Innovations in POCT

- 8.1 Sensor Systems for Diagnostic Applications
- 8.2 Glucose Measurements
- 8.3 Glucose Test Methods
- 8.4 Cholesterol Testing
- 8.5 The New Paradigm
- 8.6 Consolidated Workstations and Modularity
- 8.7 Automation and Robotics in the Clinical Laboratory
- 8.8 Laboratory Information Systems (LIS)
 - 8.8.1 NOVIUS Lab
- 8.9 Biosensor Technology
- 8.10 Nanogen Third Generation Point of Care Analyzer
- 8.11 Quidel MChip

9. Data Management and Connectivity

- 9.1 Wireless LANs
- 9.2 Connectivity Platforms
 - 9.2.1 DataLink Data Management System
 - 9.2.2 RALS-Plus
 - 9.2.2.1 International Technidyne Corporation HEMOCHRON Signature Elite
 - 9.2.2.2 Siemens Diagnostics Rapidpoint® Coag
 - 9.2.2.3 Radiometer
 - 9.2.2.4 HemoCue's DM Hemoglobin
 - 9.2.2.5 Roche Diagnostics
 - 9.2.3 BD.id
 - 9.2.4 Medical Implant Communications Service (MICS)
- 9.3 Advantages of POCT Connectivity
 - 9.3.1 Cost Benefit of POCT and IT Connectivity
 - 9.3.2 Hospital Network Issues

10. Corporate Profiles

- 10.1 Abaxis, Inc.
- 10.2 Abbott Diagnostics

- 10.3 Accumetrics, Inc.
- 10.4 Accurex Biomedical, Pvt. Ltd.
- 10.5 Akers Biosciences, Inc.
- 10.6 Alfa Scientific Design, Inc.
- 10.7 Ambri Ltd.
- 10.8 American Bio Medica Corporation
- 10.9 Ani Biotech Oy Ltd.
- 10.10 Apogent Technologies
- 10.11 Ark Therapeutics
- 10.12 Arkray, Inc.
- 10.13 Atlas Genetics
- 10.14 Atonomics
- 10.15 Avitar, Inc.
- 10.16 Augurix Diagnostics Ltd.
- 10.17 Axis-Shield
- 10.18 Beckman Coulter, Inc.
- 10.19 Binax Corporation
- 10.20 Biomerica, Inc.
- 10.21 bioMérieux Vitek, Inc.
- 10.22 BioScan Screening Systems, Inc.
- 10.23 Biosite Diagnostics
- 10.24 BioStar, Inc.
- 10.25 British Biocell Holdings
- 10.26 Caliper Life Sciences
- 10.27 Calypte Biomedical Corporation
- 10.28 Chembio Diagnostics, Inc.
- 10.29 Cholestech
- 10.30 Chongqing Sungene Pharmaceutical Co., Ltd.
- 10.31 CompuCyte Corporation
- 10.32 Cortech Diagnostics Ltd. (now Kent International Holdings)
- 10.33 Cozart Biosciences Ltd.
- 10.34 Cygnus Therapeutic Systems
- 10.35 Cytogen Corporation
- 10.36 DexCom, Inc.
- 10.37 Daiichi Sankyo Group
- 10.38 Denka Seiken Co., Ltd.
- 10.39 Diagnostic Chemicals Ltd.
- 10.40 Enigma Diagnostics Ltd.
- 10.41 Focus Diagnostics, Inc.
- 10.42 GDS Technology
- 10.43 GenBio
- 10.44 Genzyme Diagnostics
- 10.45 Grant Life Sciences, Inc.
- 10.46 Gryphus Diagnostics, LLC
- 10.47 Helena Laboratories
- 10.48 Hema Diagnostic Systems, LLC
- 10.49 Hemocue, Inc.
- 10.50 Home Access Health Corp.
- 10.51 ImmunoScience, Inc.
- 10.52 Instrumentation Laboratory

10.53 International Medical Innovations
10.54 Inverness Medical Innovations, Inc.
10.55 Johnson & Johnson
10.56 Kyowa Medex Co., Ltd.
10.57 LifeAssays
10.58 LifePoint, Inc.
10.59 LifeScan Corporation
10.60 Lifestream Technologies
10.61 LXN Corp. (Inverness Medical Technologies)
10.62 Matritech
10.63 Medical Services International, Inc.
10.64 MediSense, Inc.
10.65 Medisys
10.66 Medix Biochemica
10.67 MedMira Laboratories
10.68 Meretek Corporation
10.69 Meridian Bioscience
10.70 MiniMed, Inc.
10.71 Mitsubishi Chemical USA, Inc.
10.72 Mitsubishi Kagaku Iatron
10.73 Nanogen
10.74 New Horizons Diagnostics
10.75 Nova Biomedical
10.76 OraSure Technologies, Inc.
10.77 Orgenics
10.78 Orion Diagnostica
10.79 PanBio Ltd.
10.80 Phamatech, Inc.
10.81 Polymedco, Inc.
10.82 Polymer Technology Systems, Inc.
10.83 Princeton BioMeditech Corporation
10.84 Quest Diagnostics, Inc.
10.85 Quidel Corporation
10.86 Radiometer
10.87 Response Biomedical Corp.
10.88 Roche Diagnostics
10.89 Royal Philips Electronics
10.90 Savyon Diagnostics
10.91 Selfcare, Inc.
10.92 Shanghai Siic Kehua Biotech Co., Ltd. (Kehua Biotech)
10.93 Shionogi & Co., Ltd.
10.94 Siemens Corporation
10.95 SpectRx, Inc.
10.96 Spectral Diagnostics
10.97 StatSure Diagnostic Systems
10.98 Strategic Diagnostics, Inc.
10.99 Sun Biomedical Laboratories, Inc.
10.100 Thoratec/International Technidyne Corporation
10.101 Transmedica International, Inc.
10.102 Trinity Biotech

10.103 Väsamed, Inc.

10.104 Venkateshwara Hatcheries Pvt. Ltd.

11. POCT Sector Trends and Forecasts

11.1 Home Care Analysis as Part of Near-Patient Testing

11.2 Non-Traditional Collection for POCT

11.3 New Systems for Critical Care and Near-Patient Testing

11.4 Utility of Near-Patient Testing in Critical Care Settings

11.5 Physician's Office Market

11.6 Information Management Advances

11.7 Test-Ordering Patterns and Demand for POCT

11.8 Demand for Emergency Department Services

11.9 Move Away from Central Laboratory

11.10 Healthcare Cost Controls

11.11 M&A in POCT

11.12 Competition for Services

11.13 Drivers of POCT

11.14 Confluence of New Technology

11.15 Difficulties of Design for Point of Care Products

11.16 European Hospital Structure

11.17 The Biggest New Opportunities in POCT

12. Corporate Directory

INDEX OF FIGURES

Figure 3.1: Blood Tests Ordered in Emergency Department Visits

Figure 3.2: Worldwide Distribution of IVD Testing, 2008

Figure 3.3: Global POCT Share of Total IVD Testing Market, 2007

Figure 4.1: U.S. POCT Share of Glucose Testing Market, 2008

Figure 4.2: Number of HbA1c Tests Performed Globally as POCT, 1991-2006

Figure 4.3: Total Spending on Healthcare in the U.S., 1960-2007

Figure 4.4: International Per Capita Healthcare Spending Per Country, 2006

Figure 5.1: Global POCT Share of HIV Testing Market, 2008

Figure 6.1: Annual Rate of Emergency Room Visits by Primary Expected Source of Payment

INDEX OF TABLES

Table 2.1: Percentage of POCT Performed in Selected Hospitals

Table 2.2: POCT Procedural Advantages for Hospital Testing

Table 2.3: POCT Trends

Table 2.4: Professional POCT Compared to Home Testing

Table 2.5: Drivers for Integrating POCT into Hospital Routines

Table 3.1: Actual Reported Number of ER Visits in U.S. Hospitals, 1997-2008

Table 3.2: Number of Point of Care Tests in the U.S., 2000-2012

Table 3.3: Global Clinical Laboratory Market Sales, 1998-2011

Table 3.4: Overall IVD Testing Market Worldwide, 2007

Table 3.5: Worldwide Distribution of IVD Testing, 2008

Table 3.6: Top 12 Country IVD Testing Markets, 2007

Table 3.7: Top 13 Diagnostic Companies Worldwide, 2007
Table 3.8: Global Point of Care Revenues, 2005-2012
Table 3.9: Worldwide POCT Market Size by Geographic Location, 2005-2012
Table 3.10: Worldwide Distribution of POCT, 2008
Table 3.11: Worldwide Clinical Diagnostic POCT and Rapid Test Market Segments, 2007
Table 3.12: Worldwide POCT by Performance Location, 2008
Table 3.13: Largest POCT Diagnostic Companies Worldwide, 2007
Table 3.14: U.S. Clinical Laboratory Testing Market, 2003-2012
Table 3.15: U.S. Clinical Laboratory Diagnostic Test Market Segments by Location of Analysis, 2008
Table 3.16: U.S. POCT Market, 2000-2012
Table 3.17: U.S. POCT by Performance Location, 2008
Table 3.18: U.S. Clinical Diagnostic POCT and Rapid Test Market Segments, 2007
Table 3.19: European Clinical Laboratory Testing IVD Reagents and Instruments Market in Dollars, 2000-2012
Table 3.20: European Clinical Laboratory Testing IVD Reagents and Instruments Market in Euros, 2000-2012
Table 3.21: European Clinical Laboratory Testing Diagnostics by Country Market Estimates, 2007
Table 3.22: European Rapid POCT by Country Market Estimates, 2008
Table 3.23: Regional Comparison of Healthcare Spending for IVD for Eastern Europe
Table 3.24: European POCT Market, 2005-2012
Table 3.25: Top 12 Country IVD and POCT Markets, 2007
Table 3.26: German Clinical Laboratory Testing Diagnostics Products Market Sales, 2003-2012
Table 3.27: German POCT Diagnostics Products Market Sales, 2003-2012
Table 3.28: German Clinical Diagnostic Rapid Test Market Segments, 2007
Table 3.29: U.K. Clinical Laboratory Diagnostics Products Market Sales, 2003-2012
Table 3.30: U.K. POCT Diagnostics Products Market Sales, 2006-2012
Table 3.31: U.K. Clinical Diagnostic Rapid Test Market Segments, 2007
Table 3.32: Major U.K. IVD Manufacturers
Table 3.33: U.S. IVD Manufacturers Doing Business in the U.K.
Table 3.34: Other European Companies that Manufacture IVD Products in the U.K.
Table 3.35: French Clinical IVD Testing Diagnostics Products Market Sales, 2003-2012
Table 3.36: French POCT Diagnostics Products Market Sales, 2005-2012
Table 3.37: French Clinical Diagnostic Rapid Test Market Segments, 2007
Table 3.38: Italian Laboratory Diagnostics Products Market Sales, 2003-2012
Table 3.39: Italian POCT Diagnostics Products Market Sales, 2005-2012
Table 3.40: Italian Clinical Diagnostic Rapid Test Market Segments, 2007
Table 3.41: Spanish Clinical Laboratory Diagnostics Products Market Sales, 2003-2012
Table 3.42: Spanish Clinical Diagnostic Rapid Test Market Segments, 2007
Table 3.43: Spanish POCT Diagnostics Products Market Sales, 2005-2012
Table 3.44: Scandinavian POCT Diagnostics Products Market Sales, 2000-2012
Table 3.45: Swedish Clinical Laboratory Diagnostics Products Market Sales, 2003-2012
Table 3.46: Swedish POCT Diagnostics Products Market Sales, 2005-2012
Table 3.47: Finnish Clinical Laboratory Diagnostics Products Market Sales, 2003-2012
Table 3.48: Finnish POCT Diagnostics Products Market Sales, 2005-2012
Table 3.49: Norwegian Clinical Laboratory Diagnostics Products Market Sales, 2003-2012
Table 3.50: Norwegian POCT Diagnostics Products Market Sales, 2005-2012
Table 3.51: Swiss Clinical Laboratory Diagnostics Products Market Sales, 2003-2012
Table 3.52: Swiss POCT Diagnostics Products Market Sales, 2005-2012
Table 3.53: Dutch Clinical Laboratory Diagnostics Products Market Sales, 2003-2012
Table 3.54: Dutch POCT Diagnostics Products Market Sales, 2005-2012
Table 3.55: Belgian Clinical Laboratory Diagnostics Products Market Sales, 2003-2012
Table 3.56: Belgian POCT Diagnostics Products Market Sales, 2005-2012

Table 3.57: Portuguese Clinical Laboratory Diagnostics Products Market Sales, 2003-2012
Table 3.58: Portuguese POCT Diagnostics Products Market Sales, 2005-2012
Table 3.59: Austrian Clinical Laboratory Diagnostics Products Market Sales, 2003-2012
Table 3.60: Austrian POCT Diagnostics Products Market Sales, 2005-2012
Table 3.61: Greek Clinical Laboratory Diagnostics Products Market Sales, 2003-2012
Table 3.62: Greek POCT Diagnostics Products Market Sales, 2005-2012
Table 3.63: Polish Clinical Laboratory Diagnostics Products Market Sales, 2003-2012
Table 3.64: Polish POCT Diagnostics Products Market Sales, 2005-2012
Table 3.65: Czech Clinical Laboratory Diagnostics Products Market Sales, 2004-2012
Table 3.66: Czech POCT Diagnostics Products Market Sales, 2005-2012
Table 3.67: Turkish POCT Market, 2000-2012
Table 3.68: Japanese POCT Market, 2000-2012
Table 3.69: Japanese Population and Aging Demographics Forecast, 2000-2050
Table 3.70: Indian IVD Market for Instruments and Reagents, 2004-2012
Table 3.71: Number of Automated Clinical Labs in India, 2004-2012
Table 3.72: Indian IVD Market, 2007
Table 3.73: Indian POCT Diagnostics Products Market Sales, 2000-2012
Table 3.74: Chinese IVD Market, 2006-2012
Table 3.75: Number of Automated Clinical Labs in China, 2004-2012
Table 3.76: Chinese IVD Market, 2007
Table 3.77: Chinese POCT Diagnostics Products Market Sales, 2000-2012
Table 3.78: Rest of the World POCT Market, 2000-2012
Table 3.79: Canadian POCT Market, 2000-2012
Table 3.80: Brazilian POCT Market, 2000-2012
Table 3.81: Australian POCT Market, 2000-2012
Table 4.1: World Market Share of Point of Care Glucose Monitoring Marketers
Table 4.2: Global Population of Persons with Diabetes, 1995 and 2025
Table 4.3: Professional Glucose Testing Market for POCT Worldwide, 2001-2012
Table 4.4: U.S. Point of Care Glucose Testing Market, 1997-2012
Table 4.5: Manufacturer Market Share U.S. POCT Market, 2008
Table 4.6: Rapid Testing U.S. Market Share for Blood Glucose Testing Segment
Table 4.7: HbA1c Testing Market for POCT Worldwide, 2006-2012
Table 4.8: Critical Care Blood Gas Testing Market for POCT Worldwide, 2006-2012
Table 4.9: Blood Gas and Electrolyte Market for POCT in the U.S., 2001-2012
Table 4.10: Location Market Share of Critical Care Blood Gas Testing, 1990 and 2008
Table 4.11: Manufacturer Market Share U.S. POCT Blood Gas and Electrolytes Market, 2007
Table 4.12: Hospital Locations of Point of Care Coagulation Testing
Table 4.13: Drivers for Point of Care Coagulation Testing
Table 4.14: Barriers for Point of Care Coagulation Testing
Table 4.15: Coagulation Testing Market for POCT Worldwide, 2006-2012
Table 4.16: Handheld Coagulation Testing Market for POCT Worldwide, 2006-2012
Table 4.17: Coagulation Market for POCT in the U.S., 2001-2012
Table 4.18: Point of Care Prothrombin Market for POCT in the U.S., 2000-2008
Table 4.19: Cardiac Marker Market for POCT in the U.S., 2001-2012
Table 4.20: Cardiac Marker Market for POCT Worldwide, 2001-2012
Table 4.21: Manufacturer Market Share U.S. POCT Cardiac Marker Market, 2007
Table 4.22: Cardiac Marker Market for POCT in Europe, 2001-2011
Table 4.23: Drugs of Abuse Testing Market for POCT Worldwide, 2006-2012
Table 4.24: U.S. Point of Care Drugs of Abuse Testing Market, 2006-2012
Table 4.25: Drug Testing Needs Tier I for Rapid Serum POCT in the Emergency Department

Table 4.26: Stat Urine Testing Drug Recommendations
Table 4.27: Device Specifications for POCT Breath Alcohol Analysis
Table 4.28: Global Point of Care Urine Test Strip Testing Market, 2001-2008
Table 4.29: Global Point of Care Urine Test Strip POCT Testing Market, 2006-2012
Table 4.30: U.S. Point of Care Urine Test Strip Testing Market, 2001-2011
Table 4.31: U.S. Point of Care Urine Test Strip Testing Market Share
Table 4.32: Medicare Fee Schedule for Urine Chemistry Testing, 2003
Table 4.33: Pregnancy Testing Market for POCT Worldwide, 2006-2012
Table 4.34: U.S. Point of Care Pregnancy Testing Market, 2001-2012
Table 4.35: International Point of Care Pregnancy Testing Markets, 2001-2007
Table 4.36: U.S. Market Share for Rapid Point of Care Pregnancy Tests
Table 4.37: Hemoglobin Testing Market for POCT Worldwide, 2006-2012
Table 4.38: Drivers of Demand for HIV Testing
Table 4.39: Worldwide POCT Market for HIV, 2001-2012
Table 4.40: U.S. POCT Market for HIV, 2001-2012
Table 4.41: Countries with the Highest Prevalence of HIV/AIDS
Table 4.42: FDA-approved Rapid HIV Antibody Screening Tests
Table 4.43: OraSure OraQuick Rapid HIV Test Revenues, 2008
Table 4.44: Cholesterol Testing Market for POCT Worldwide, 2006-2012
Table 4.45: Infectious Disease Testing Market for POCT Worldwide, 2006-2012
Table 4.46: Salmonella Testing Market, 2002-2007
Table 4.47: Worldwide Point of Care Influenza Testing Market, 2002-2007
Table 4.48: U.S. Point of Care Influenza Testing Market, 2002-2007
Table 4.49: International Point of Care Influenza Testing Markets, 2002-2007
Table 4.50: U.S. Market for Rapid Point of Care Influenza Tests, 2007
Table 4.51: Worldwide Point of Care Strep A Testing Market, 2002-2007
Table 4.52: U.S. Point of Care Strep A Testing Market, 2002-2007
Table 4.53: International Point of Care Strep A Testing Markets, 2002-2007
Table 4.54: U.S. Market for Rapid Point of Care for Group A Strep Tests
Table 4.55: Global Market for Chlamydia Diagnostic Testing, 2000-2009
Table 4.56: U.S. Market for Chlamydia Diagnostic Testing, 2000-2009
Table 4.57: U.S. Market for MRSA Rapid Testing, 2006-2013
Table 4.58: Global Market for Gonorrhea Diagnostic Testing, 2000-2009
Table 4.59: Global Market for TB Diagnostic Testing, 2000-2008
Table 4.60: U.S. Anthrax Test Market
Table 5.1: Largest U.S. POCT Coagulation Diagnostic Testing Companies, 2008
Table 5.2: Actalyke XL
Table 5.3: Actalyke Mini
Table 5.4: Drug Test Sensitivity Cut-Off Levels Set by NIDA, WHO and SAMHSA for Drugs of Abuse
Table 5.5: Major Competitors in the Drugs of Abuse Testing Market Segment
Table 5.6: Major Competitors in the Drugs of Abuse Oral Testing Market Segment
Table 5.7: Major Competitors in the Drugs of Abuse Urine Testing Market Segment
Table 5.8: Major Competitors in the Drugs of Abuse Saliva Testing Market Segment
Table 5.9: Siemens Urinalysis Near-Patient Devices
Table 5.10: ColoCARE Fecal Occult Blood Test
Table 5.11: Competitive Factors Related to HIV Tests
Table 5.12: Largest POCT Diagnostic Companies Worldwide, 2008
Table 5.13: Type of Hepatitis Test: Lateral Flow
Table 5.14: Flow-through
Table 5.15: Agglutination

Table 5.16: Immunoblot

Table 5.17: AmniSure

Table 6.1: Access Points

Table 6.2: Desktop Adapters-Four Computers

Table 6.3: Desktop Adapters-One Computer

Table 6.4: PCMCIA Adapters

Table 6.5: POCT1-Compliant Connectivity Point of Care Instruments

Table 6.6: POCT Clinical Outcomes in Diabetic Ketoacidosis

Table 6.7: POCT Clinical Outcomes in Arterial Blood Gas Measurements

Table 6.8: POCT in Three Hospitals-Cost Analysis with Labor Included

Table 6.9: POCT versus Central Lab-Cost Analysis for Glucose Testing

Table 6.10: Financial Comparison for Moderate and Waived CLIA Labs

Table 7.1: Key Changes in IVD Business Structure

Table 7.2: Business Trends in POCT

Table 7.3: Key Players Bring Business Developments to Point of Care Diagnostic Testing

Table 8.1: Normal Glucose Values-Fasting State

Table 9.1: Applications for Wireless LAN Technology

Table 9.2: Customized Reports Must Support CAP and JCAHO Requirements

Table 9.3: RALS-Plus Point of Care Market Share

Table 9.4: Applications of RALS Connectivity with POCT Devices

Table 10.1: Abaxis Blood Analysis Diagnostic Tests

Table 10.2: Reagent Discs Offered with the Piccolo Chemistry Analyzers

Table 10.3: Products Marketed by Abbott in the Diagnostic Market

Table 10.4: Inverness Brands

Table 10.5: Orasure's Products

Table 10.6: Quidel Product Sales Distribution and Sales, 2008

Table 11.1: Improvements in Achieving ED Operational Efficiency Using POCT

Table 11.2: Test Menu and TAT for ED

Table 11.3: Top Reasons Why Point of Care Cardiac Marker Testing is Implemented in the ED

Table 11.4: Key Areas and Metrics that Hospitals Measure to Assess Efficiency of ED

Table 11.5: Estimates of Patient Costs by DRG

Fax Order Form

To place an order via fax simply print this form, fill in the information below and fax the completed form to **(805) 617 17 93** . If you have any questions please visit <http://www.reportlinker.com/notify/contact>

Order Information

Please verify that the product information is correct and select the format(s) you require.

[Point of Care Diagnostic Testing World Markets](#)

Product Formats

Please select the product formats and the quantity you require.

- 1 User License -- USD 3 400.00 Quantity: _____
- Corporate License -- USD 6 800.00 Quantity: _____

Contact Information

Please enter all the information below in **BLOCK CAPITALS**

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____ Last Name: _____

Email Address: _____

Job Title: _____

Organization: _____

Address: _____

City: _____

Postal / Zip Code: _____

Country: _____

Phone Number: _____

Fax Number: _____

Payment Information

Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: _____

Expiry Date _____ / _____

CVV Number _____

Card Type (ex: Visa, Amex...) _____

Payment by wire transfer Crédit Mutuel

RIB : 10278 07314 00020257701 78

BIC : CMCIFR2A

IBAN : FR76 1027 8073 1400 0202 5770 178

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at

<http://www.reportlinker.com/index/terms>

Please fax this form to

(805) 617 17 93